曼乐静®褪黑素颗粒临床数据显示，服用该产品可显著缩短患儿入睡潜伏期，长期使用还能改善异常行为（如易激惹、多动、语言不当）。在安全性方面， 为期半年的随访观察发现，其无严重不良反应、也无依赖性和戒断风险，适合儿童长期服用。 达因药业以"使千千万万中国儿童健康强壮"为使命，始终聚焦于儿童专用药物和营养健康产品的研发与引进。公司负责人曾多次强调"量身定制儿童药 物"和"质量源于设计"的研发理念，选择阿里健康作为合作平台，则是看中了其精准连接海量潜在用户、并提供专业药事服务的能力，面对神经发育障碍儿 童睡眠问题这一专业领域，平台可通过权威内容帮助家长建立科学认知，并借助严格的处方药流程确保用药安全。同时，便捷的配送服务和后续的药学支 持，能让家庭护理变得更加可持续。 阿里健康相关业务负责人表示："与达因药业的全面战略合作，是我们深耕垂直人群健康管理的重要布局。它再次印证了阿里健康作为'新特药首发阵地'的 定位——我们不仅是新品发布的窗口，更是通过整合生态资源，为药企提供从市场洞察、精准触达到患者服务的完整解决方案，最终让前沿、专业的治疗选 择能够高效、可信地惠及中国家庭。"未来，双方将继续在儿童健康领域深化合作，探索 ...

Core Insights - The company is transitioning from a "growth hormone monoclonal drive" to a "children's health platform enterprise," showcasing its commitment to continuous innovation in pediatric healthcare [1][10] - The founder and CEO, Dr. Jin Lei, highlighted the importance of enhancing the medication experience for children, which directly impacts treatment adherence and outcomes [3][10] R&D Achievements - The company launched the world's first long-acting growth hormone in 2014, reducing injection frequency from daily to weekly, and has invested 300 million RMB in direct costs from 2015 to 2025 to improve production processes [3] - The serious adverse reaction rate for the long-acting growth hormone, JinSaiZeng, is maintained below 0.01%, demonstrating superior product quality compared to international counterparts [3] Technological Advancements - The long-acting protein technology platform is a cornerstone for the company's strategic transformation, with ongoing development of monthly formulations like GenSci134 [4] - The unique "U-shaped PEG" technology addresses common industry challenges such as immunogenicity and pharmacokinetic instability, showcasing the platform's adaptability and industrial stability [4] Diversification Strategy - The company is expanding its pipeline to include various therapeutic areas such as endocrine metabolism, allergies, and neurological disorders, aligning with the trend of comprehensive health management for children [6][7] - Collaborative efforts with hospitals to establish pediatric chronic disease management centers reflect the company's commitment to addressing multiple chronic conditions in children [7] Strategic Product Focus - Three key strategic products are highlighted: - GenSci073, an oral growth hormone secretagogue, which could revolutionize treatment by eliminating the need for injections [8] - JinBeiXin, targeting systemic juvenile idiopathic arthritis, addressing unmet clinical needs in rare diseases [8] - AnTuoDa, a sublingual desensitization tablet for allergic diseases, combining professional medical attributes with consumer convenience [8] Investment and Global Expansion - The company has achieved continuous growth in R&D investment for 12 years and is constructing a global innovation R&D center in Shanghai, expected to be operational by 2026 [9] - The shift from a "China market capability" focus to a "global innovation + China market" dual-driven development model indicates the company's ambition to enhance its international competitiveness [9] Industry Implications - The company's strategic approach illustrates a pathway for Chinese pharmaceutical companies to evolve from "product companies" to "platform-based healthcare enterprises," emphasizing the need for a sustainable medical ecosystem that meets clinical demands [10]